zhangzhao gao

Dr. zhangzhao gao

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
ZGzhangzhao gao
zhangzhao gao
JJJing-Yu Jiao
Jing-Yu Jiao
YZYa-Qiong Zhou
Ya-Qiong Zhou
JQJian Qi
Jian Qi
SZShan-Shan Zhu
Shan-Shan Zhu
HWHaibin Wang
Haibin Wang

20 November 2024 in Antibodies
Verified
Journal Article
Open access
PDF file
YZYaqiong Zhou
Yaqiong Zhou
YWYIRU WANG
YIRU WANG
JLJinfeng Liang
Jinfeng Liang
JQJing Qian
Jing Qian
ZWZhen-Hua Wu
Zhen-Hua Wu
HWHaibin Wang
Haibin Wang
Immuno-oncology has revolutionized cancer treatment, with NKG2A emerging as a novel target for immunotherapy. The blockade of NKG2A using the immune checkpoint inhibitor (ICI) monalizumab has been shown to enhance the responses of both NK cells and CD8+ T cells. However, monalizumab has demonstrated limited efficacy in in vitro cytotoxic assays and clinical trials. In our study, we discovered and characterized a novel anti-NKG2A antibody, BRY805, which exhibits high specificity for the human CD94/NKG2A heterodimer complex and does not bind to the activating NKG2C receptor. In vitro cytotoxicity assays demonstrated that BRY805 effectively activated NK92 cells and primary NK cells, thereby enhancing the cytotoxic activity of effector cells against cancer cells overexpressing HLA-E, with significantly greater efficacy compared to monalizumab. Furthermore, BRY805 exhibited synergistic antitumor activity when combined with PD-L1 monoclonal antibodies. In a mouse xenograft model, BRY805 showed superior tumor control relative to monalizumab and demonstrated a favorable safety profile in non-human primate studies.